APP Intensive IO Resectable Nonmetastatic NSCLC

CE / CME

Applying Evidence for Immunotherapy in Resectable Nonmetastatic NSCLC

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Released: July 29, 2024

Expiration: July 28, 2025

Marianne Davies
Marianne Davies, DNP, ACNP, AOCNP, FAAN
Kelly E.H. Goodwin
Kelly E.H. Goodwin, NP

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

In the phase III CheckMate 816 trial in patients with resectable NSCLC, which of the following outcomes were significantly improved with the addition of nivolumab to neoadjuvant chemotherapy? 

2.

Based on available evidence, patients with resectable early-stage NSCLC and which of the following levels of PD-L1 expression may benefit from perioperative (neoadjuvant and adjuvant) nivolumab or pembrolizumab? 

3.

Patient Case: Newly Diagnosed Metastatic NSCLC



  • 60-yr-old woman with a smoking history diagnosed with bilateral lung adenocarcinoma, mediastinal and bilateral supraclavicular adenopathy, with metastases to liver

    • PD-L1 40%; NGS positive for KRAS G12V mutation

    • PMH of osteoarthritis; eGFR 60 mL/min.

    • Symptomatic with need for supplemental O2

    • MRI brain negative for metastases



Which of the following would be most appropriate for this patient? 

4.

Patient Case: ILD/Pneumonitis on Chemoimmunotherapy



  • 62-yr-old woman with stage IV (metastatic) lung adenocarcinoma currently on maintenance chemoimmunotherapy

    • She is now presenting for consideration of cycle 7

    • She reports worsening SOB and cough

    • SpO2 saturation with ambulation is 90% in the clinic

    • Urgent CT of chest shows bilateral opacities



Which of the following is NOT a strategy for effectively mitigating and managing suspected ILD/pneumonitis with chemoimmunotherapy?